|
EIF4G2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.3793999997791E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.6809199999912E-05 |
| Normal-vs-Stage2 |
2.164100E-03 |
| Normal-vs-Stage3 |
5.89519999483201E-08 |
| Normal-vs-Stage4 |
6.38630004434759E-09 |
| Stage1-vs-Stage2 |
7.243600E-01 |
| Stage1-vs-Stage3 |
3.108200E-02 |
| Stage1-vs-Stage4 |
3.435000E-03 |
| Stage2-vs-Stage3 |
8.002100E-02 |
| Stage2-vs-Stage4 |
1.736460E-02 |
| Stage3-vs-Stage4 |
4.197200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.95120000046067E-07 |
| Normal-vs-AfricanAmerican |
1.197830E-02 |
| Normal-vs-Asian |
1.54175000000034E-05 |
| Caucasian-vs-AfricanAmerican |
4.025000E-01 |
| Caucasian-vs-Asian |
5.571400E-01 |
| AfricanAmerican-vs-Asian |
2.464800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.52049999988269E-07 |
| Normal-vs-Female |
5.26490000041235E-07 |
| Male-vs-Female |
2.878200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.202060E-04 |
| Normal-vs-Age(41-60Yrs) |
6.28210000019891E-07 |
| Normal-vs-Age(61-80Yrs) |
1.07219999545549E-08 |
| Normal-vs-Age(81-100Yrs) |
3.153800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.357220E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.754500E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.127800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.455400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.136200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.264800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.255220E-01 |
| Classical-VS-Follicular |
8.610200E-01 |
| Classical-VS-Other |
2.220400E-01 |
| Classical-VS-Normal |
1.09219999999688E-06 |
| Tall-VS-Follicular |
1.282770E-01 |
| Tall-VS-Other |
6.660400E-01 |
| Tall-VS-Normal |
1.62421999999607E-05 |
| Follicular-VS-Other |
2.941600E-01 |
| Follicular-VS-Normal |
5.631600E-04 |
| Other-VS-Normal |
4.096300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.87449999999867E-06 |
| Normal-vs-N1 |
1.46599999917285E-08 |
| N0-vs-N1 |
2.439500E-02 |
|
|
